Desidustat
- Generic Name
- Desidustat
- Drug Type
- Small Molecule
- Chemical Formula
- C16H16N2O6
- CAS Number
- 1616690-16-4
- Unique Ingredient Identifier
- Y962PQA4KS
- Background
Desidustat is under investigation in clinical trial NCT04012957 (Desidustat in the Treatment of Anemia in CKD).
Zydus Healthcare Secures CDSCO Approval for Phase III Trials of Two COPD Combination Therapies
• Zydus Healthcare has received approval from India's CDSCO panel to conduct Phase III clinical trials for Glycopyrrolate-Indacaterol metered dose inhalation, a maintenance treatment for COPD patients.
• The company also secured approval for Phase III trials of Vilanterol-Umeclidinium powder inhalation, with the condition that severe COPD patients with inspiratory flow rates below 30 L/min be excluded.
• Both combination therapies target bronchodilation through different mechanisms - LAMA/LABA combinations that improve airflow obstruction in COPD by relaxing bronchial smooth muscles.
Zydus and ICMR Partner to Initiate Phase 2 Trial of Desidustat for Sickle Cell Disease
• Zydus Lifesciences and the Indian Council of Medical Research (ICMR) have partnered to begin Phase 2 clinical trials of Desidustat for sickle cell disease.
• The Phase IIa trial is a double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of oral Desidustat.
• The primary endpoint is the proportion of patients with a hemoglobin response (≥1 g/dL increase) compared to placebo at weeks 4 and 8.
• Desidustat, a HIF-prolyl hydroxylase inhibitor, aims to address the unmet need for effective sickle cell disease treatments beyond hydroxyurea.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath